Erysipelas: Difference between revisions
No edit summary |
|||
Line 14: | Line 14: | ||
==Treatment== | ==Treatment== | ||
===[[Antibiotics]]=== | |||
{{Erysipelas antibiotics}} | |||
==Source== | ==Source== |
Revision as of 18:25, 21 April 2015
Background
- Specific form of cellulitis involving the epidermis, upper levels of the dermis, and the lymphatics
- Most often caused by strep
- Bullous erysipelas, a more severe form of the disease, is often caused by staph (and MRSA)
Diagnosis
- Often accompanied by fever, chills, malaise, HA, vomiting
- Rash
- Local redness, heat, swelling
- Sharp raised and indurated border
Differential Diagnosis
Skin and Soft Tissue Infection
- Cellulitis
- Erysipelas
- Lymphangitis
- Folliculitis
- Hidradenitis suppurativa
- Skin abscess
- Necrotizing soft tissue infections
- Mycobacterium marinum
Look-A-Likes
- Sporotrichosis
- Osteomyelitis
- Deep venous thrombosis
- Pyomyositis
- Purple glove syndrome
- Tuberculosis (tuberculous inflammation of the skin)
Treatment
Antibiotics
Coverage for S. pyogenes
- Penicillin G 300K U/d IM for <30 kg, 600K to 1 million U/d IM for >30 kg (first line therapy[1]) OR
- Clindamycin 450mg (5mg/kg) PO q8hrs x 10 days (if PCN allergic) OR
- Cephalexin 500mg (6.25mg/kg) PO q6hrs x 10 days OR
- Ceftriaxone 1g (50mg/kg) IV once daily x 10 days OR
- Levofloxacin 500mg PO/IV daily x 10 days OR
- Augmentin 500mg PO BID x 10 days (generally reserved for failure of first line therapy)
Bullous Erysipela or MRSA suspected: trimethoprim-sulfamethoxazole, clindamycin, doxycycline, or minocycline
Source
- Tintinalli
- ↑ Linke M, Booken N. Risk factors associated with a reduced response in the treatment of erysipelas. J Dtsch Dermatol Ges. 2015 Mar;13(3):217-25.